Literature DB >> 15126528

Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study.

Saara Taponen1, Hannu Martikainen, Marjo-Riitta Järvelin, Ulla Sovio, Jaana Laitinen, Anneli Pouta, Anna-Liisa Hartikainen, Mark I McCarthy, Stephen Franks, Mika Paldanius, Aimo Ruokonen.   

Abstract

The metabolic cardiovascular disease (CVD) risk factors of women with self-reported oligomenorrhea and/or hirsutism, which are symptoms of polycystic ovary syndrome (PCOS), were investigated in a general population-based Northern Finland Birth Cohort 1966 Study to determine whether women with PCOS symptoms at 31 yr would be distinguishable from asymptomatic controls in terms of CVD risk factors. A total of 518 cases with oligomenorrhea and/or hirsutism and 1036 randomly selected controls were analyzed. C-Reactive protein (CRP; median, 0.70 vs. 0.60 mg/liter; P = 0.026), triglycerides (mean, 0.97 vs. 0.91 mmol/liter; P = 0.039), body mass index (BMI; mean, 25.1 vs. 24.2 kg/m(2); P < 0.001), and waist/hip ratio (mean, 0.82 vs. 0.81; P = 0.001) were significantly higher, and high-density lipoprotein cholesterol levels were lower (mean, 1.60 vs. 1.66 mmol/liter; P = 0.002) in the cases compared with the controls. Total cholesterol, low-density lipoprotein cholesterol, and blood pressure showed no statistically significant differences between the cases and the controls. In terms of metabolic CVD risk factors, women reporting hirsutism alone were indistinguishable from the control group, and those who reported both oligomenorrhea and hirsutism had the most severe changes in risk factor profiles. Because obesity is strongly related to PCOS symptoms, the analyses were stratified by BMI. After stratification into normal weight (BMI, <25 kg/m(2)), overweight (25 kg/m(2) <or= BMI <30 kg/m(2)), and obese (BMI, >or=30 kg/m(2)) groups, the waist/hip ratio was significantly higher among the overweight cases (mean, 0.84 vs. 0.83; P = 0.04). Among the obese women, high-density lipoprotein cholesterol was significantly lower (mean, 1.32 vs. 1.48 mmol/liter; P = 0.002) among the cases, and triglycerides tended to be higher (mean, 1.43 vs. 1.27 mmol/liter; P = 0.068) than in controls. In conclusion, these results indicate that self-reported symptoms of oligomenorrhea and/or hirsutism, particularly in the presence of both symptoms, may be helpful to identify women with metabolic cardiovascular risk factor accumulation associated with PCOS.

Entities:  

Mesh:

Year:  2004        PMID: 15126528     DOI: 10.1210/jc.2003-031720

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Distinct variants at LIN28B influence growth in height from birth to adulthood.

Authors:  Elisabeth Widén; Samuli Ripatti; Diana L Cousminer; Ida Surakka; Tuuli Lappalainen; Marjo-Riitta Järvelin; Johan G Eriksson; Olli Raitakari; Veikko Salomaa; Ulla Sovio; Anna-Liisa Hartikainen; Anneli Pouta; Mark I McCarthy; Clive Osmond; Eero Kajantie; Terho Lehtimäki; Jorma Viikari; Mika Kähönen; Chris Tyler-Smith; Nelson Freimer; Joel N Hirschhorn; Leena Peltonen; Aarno Palotie
Journal:  Am J Hum Genet       Date:  2010-04-15       Impact factor: 11.025

Review 2.  The metabolic syndrome in polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 3.  Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.

Authors:  Laura C Torchen
Journal:  Curr Diab Rep       Date:  2017-11-11       Impact factor: 4.810

4.  Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease.

Authors:  Andrew J Krentz; Denise von Mühlen; Elizabeth Barrett-Connor
Journal:  Menopause       Date:  2007 Mar-Apr       Impact factor: 2.953

5.  No association between insulin gene variation and adult metabolic phenotypes in a large Finnish birth cohort.

Authors:  A Bennett; U Sovio; A Ruokonen; H Martikainen; A Pouta; S Taponen; A-L Hartikainen; S Franks; L Peltonen; P Elliott; M-R Järvelin; M I McCarthy
Journal:  Diabetologia       Date:  2005-04-16       Impact factor: 10.122

6.  Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia.

Authors:  Erica T Wang; Ronit Calderon-Margalit; Marcelle I Cedars; Martha L Daviglus; Sharon S Merkin; Pamela J Schreiner; Barbara Sternfeld; Melissa Wellons; Stephen M Schwartz; Cora E Lewis; O Dale Williams; David S Siscovick; Kirsten Bibbins-Domingo
Journal:  Obstet Gynecol       Date:  2011-01       Impact factor: 7.661

7.  Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives.

Authors:  Richard S Legro; Rebecca L Roller; William C Dodson; Christina M Stetter; Allen R Kunselman; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

9.  Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study.

Authors:  S West; H Lashen; A Bloigu; S Franks; K Puukka; A Ruokonen; M-R Järvelin; J S Tapanainen; L Morin-Papunen
Journal:  Hum Reprod       Date:  2014-08-01       Impact factor: 6.918

10.  Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome.

Authors:  T M Barber; A J Bennett; C J Groves; U Sovio; A Ruokonen; H Martikainen; A Pouta; A-L Hartikainen; P Elliott; C M Lindgren; R M Freathy; K Koch; W H Ouwehand; F Karpe; G S Conway; J A H Wass; M-R Järvelin; S Franks; M I McCarthy
Journal:  Diabetologia       Date:  2008-05-14       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.